AnaptysBio Inc. (ANAB) shares plummeted 5.37% during intraday trading on Thursday, as investor sentiment turned negative following the disclosure of significant risks associated with the company's proposed corporate breakup.

The biopharmaceutical company has highlighted new risks in the Corporate Activity and Growth category, specifically noting that it may fail to realize the expected operational benefits from the planned separation. Market concerns are centered on potential challenges related to market value, increased volatility, and execution hurdles that could arise from the complex corporate action.

This negative development overshadowed other positive analyst actions, including Stifel's upgrade of its price target on the stock, as investors focused on the uncertainties surrounding the company's strategic reorganization plan.